Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A while. There’s been loading in this area so I expect a move on the next news.
35 wall falling. Time to get in on dip opportunities. I would not be surprised to see green today.
Sounds good.
Fantastic! Slowly moving back up. Let’s see what later today and next week brings.
Nice summary. Thanks
Nice!
Can you elaborate on those catalysts?
Yup. Once cfgn is cleared here it will move back up. He should be almost done given the volume imo
Second push higher coming this afternoon. I see a .0050 plus close going into the weekend. .01 next week. Jmo
Nice Sub! Huge buying going on. This will move back up.
Looking for a red to Green Day here into the weekend. This company is just getting started. Peer reviews/further clinical trials. We may have if the few early treatments available for the virus/disease among other really important immune therapies for cancer etc. This is a diamond in the rough.
Absolutely sub. Here we have a safe preventative with already positive pre clinical trials. This will be huge imo
Cfgn is gone. Looks like that note is gone. Only gtsm. They will be gone soon imo.
Dip and rip.
Here is the manuscript of the Preclinical and Clinical Evaluation of Nutritional Supplement Designed to Protect Against COVD-19
https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf
That’s ridiculous. He posts dozens of the highest volume stocks each day. He just plays the chart.
Man your negative. Relax. You were complaining yesterday and look where it is now.
Here we go...
60s about to break.
Wow. That’s important to know.
Looks a lot thinner now. New HOD coming!
People have to realize that one of San Diego’s top doctors is supporting this drug. I assume he has high level connections as well.
Getting ready for power hour and gap up tomorrow.
Let’s see nhod soon.
Nice to see you here UpTrend!
Exactly. That’s why I think this trial gives so much hope that there could be a viable preventative solution. Will be interesting to see the clinical trial peer reviewed and further trials begin.
This clinical trial is huge. If further clinical trials prove its efficacy this could rival GILD’s Remdesivir only that this prevents hospitalizations rather than shorten it.
Agreed. That was a patent. This was as actual trial that showed efficacy.
That’s important info as safety profile is key.
This news is bigger than SBFM. That was a patent. This was an actual positive clinical trial.
TSOI...Huge News...Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVD-19
Company Submits Results of Clinical Trial for Publication in Peer-Reviewed Medical Journal
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/stock-news/82600993/therapeutic-solutions-international-announces-posi
OCEANSIDE, CA -- June 4, 2020 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy volunteers between 18-65 years of age, lacking chronic or active disease.
The study comprised of 4 groups of patients who received QuadraMune™, or placebo. Group 1 was placebo control, Group 2, received 2 capsules per day, group 3 received 4 capsules per day, and group 4 received 8 capsules per day. The trial lasted 7 days. QuadraMune™ was provided by Therapeutic Solutions International.
"To date, there are no FDA cleared means of preventing COVID-19. Despite work being performed at "Warp-Speed" towards vaccine development, these efforts are still believed to be months if not years away" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and "Top Doctor" of San Diego in 2012, 2014, 2016, 2017, and 2019. "We aimed to perform a series of experiments to assess preclinical and pilot clinical feasibility of QuadraMune™ to address the issue of immune stimulation while inhibiting inflammation. The current data strongly supports that the combination of natural ingredients in QuadraMune™ possesses a synergistic effect at suppressing key components of "Cytokine Storm", namely interleukin-6 and TNF-alpha. If studies continue to support these conclusions, future use of QuadraMune™ in conditions such as cancer inflammation and rheumatoid arthritis will be considered."
The cytokine interleukin-6 is considered a cornerstone of the inflammatory response. Suppression of interleukin-6 for pathological inflammation, such as in rheumatoid arthritis, is the basis of the drug Actemra (Tocilizumab). Manufactured by Roche, this drug had sales of $2.4 billion dollars last year [1].
"In vivo administration of QuadraMune™ was successful in stimulating markers of immunity both at the level of the innate immune response, and adaptive immune responses," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "Many approaches that suppress inflammation also suppress immunity. In order to have a fighting chance, any approach being developed for this condition must induce both the suppression of inflammation and the activation of immunity. These early data support this statement."
The Company plans to expand clinical trials to patients suffering from COVID-19 and/or individuals at risk of COVID-19. A pre-publication copy, of the submitted manuscript, is available by following this link: https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visit www.areyoucovidmune.com/covidmune/.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
[1] https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
Therapeutic Solutions International, Inc.
ir@tsoimail.com
TSOI...big news out...Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVD-19
Company Submits Results of Clinical Trial for Publication in Peer-Reviewed Medical Journal
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/stock-news/82600993/therapeutic-solutions-international-announces-posi
OCEANSIDE, CA -- June 4, 2020 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy volunteers between 18-65 years of age, lacking chronic or active disease.
The study comprised of 4 groups of patients who received QuadraMune™, or placebo. Group 1 was placebo control, Group 2, received 2 capsules per day, group 3 received 4 capsules per day, and group 4 received 8 capsules per day. The trial lasted 7 days. QuadraMune™ was provided by Therapeutic Solutions International.
"To date, there are no FDA cleared means of preventing COVID-19. Despite work being performed at "Warp-Speed" towards vaccine development, these efforts are still believed to be months if not years away" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and "Top Doctor" of San Diego in 2012, 2014, 2016, 2017, and 2019. "We aimed to perform a series of experiments to assess preclinical and pilot clinical feasibility of QuadraMune™ to address the issue of immune stimulation while inhibiting inflammation. The current data strongly supports that the combination of natural ingredients in QuadraMune™ possesses a synergistic effect at suppressing key components of "Cytokine Storm", namely interleukin-6 and TNF-alpha. If studies continue to support these conclusions, future use of QuadraMune™ in conditions such as cancer inflammation and rheumatoid arthritis will be considered."
The cytokine interleukin-6 is considered a cornerstone of the inflammatory response. Suppression of interleukin-6 for pathological inflammation, such as in rheumatoid arthritis, is the basis of the drug Actemra (Tocilizumab). Manufactured by Roche, this drug had sales of $2.4 billion dollars last year [1].
"In vivo administration of QuadraMune™ was successful in stimulating markers of immunity both at the level of the innate immune response, and adaptive immune responses," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "Many approaches that suppress inflammation also suppress immunity. In order to have a fighting chance, any approach being developed for this condition must induce both the suppression of inflammation and the activation of immunity. These early data support this statement."
The Company plans to expand clinical trials to patients suffering from COVID-19 and/or individuals at risk of COVID-19. A pre-publication copy, of the submitted manuscript, is available by following this link: https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visit www.areyoucovidmune.com/covidmune/.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
[1] https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
Therapeutic Solutions International, Inc.
ir@tsoimail.com
TSOI...Huge News...Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVD-19
Company Submits Results of Clinical Trial for Publication in Peer-Reviewed Medical Journal
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-pk-TSOI/stock-news/82600993/therapeutic-solutions-international-announces-posi
OCEANSIDE, CA -- June 4, 2020 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy volunteers between 18-65 years of age, lacking chronic or active disease.
The study comprised of 4 groups of patients who received QuadraMune™, or placebo. Group 1 was placebo control, Group 2, received 2 capsules per day, group 3 received 4 capsules per day, and group 4 received 8 capsules per day. The trial lasted 7 days. QuadraMune™ was provided by Therapeutic Solutions International.
"To date, there are no FDA cleared means of preventing COVID-19. Despite work being performed at "Warp-Speed" towards vaccine development, these efforts are still believed to be months if not years away" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International and "Top Doctor" of San Diego in 2012, 2014, 2016, 2017, and 2019. "We aimed to perform a series of experiments to assess preclinical and pilot clinical feasibility of QuadraMune™ to address the issue of immune stimulation while inhibiting inflammation. The current data strongly supports that the combination of natural ingredients in QuadraMune™ possesses a synergistic effect at suppressing key components of "Cytokine Storm", namely interleukin-6 and TNF-alpha. If studies continue to support these conclusions, future use of QuadraMune™ in conditions such as cancer inflammation and rheumatoid arthritis will be considered."
The cytokine interleukin-6 is considered a cornerstone of the inflammatory response. Suppression of interleukin-6 for pathological inflammation, such as in rheumatoid arthritis, is the basis of the drug Actemra (Tocilizumab). Manufactured by Roche, this drug had sales of $2.4 billion dollars last year [1].
"In vivo administration of QuadraMune™ was successful in stimulating markers of immunity both at the level of the innate immune response, and adaptive immune responses," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "Many approaches that suppress inflammation also suppress immunity. In order to have a fighting chance, any approach being developed for this condition must induce both the suppression of inflammation and the activation of immunity. These early data support this statement."
The Company plans to expand clinical trials to patients suffering from COVID-19 and/or individuals at risk of COVID-19. A pre-publication copy, of the submitted manuscript, is available by following this link: https://therapeuticsolutionsint.com/CV/JTRM-D-20-01014.pdf
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visit www.areyoucovidmune.com/covidmune/.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
[1] https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines
Therapeutic Solutions International, Inc.
ir@tsoimail.com
Wow! Huge news!
Well said Smart Money. Like you said before the s1 is at .0030 so I expect they take it much higher on those 160 mil shares. Let’s see this move up from here.
Thanks. Have a great day!
This is from the S1:
Immune-Oncology – Right To Try
In May of 2018 President Donald J. Trump signed into the law, the Right To Try bill. In 2015/2016 TSOI began and completed a 10 patient clinical trial of advanced cancer patients in Mexico at the Pan Am Cancer Treatment Center located in Tijuana Mexico using our dendritic cell vaccine code named StemVacs. TS O I has since generated GCP documentation for the previously treated 10 patients into a Phase I trial, which will be presented to the FDA by TS O I as part of an Ex-US trial compliant with 21 CFR 312.120 Foreign clinical studies not conducted under an IND. This is a required step to conform to the new Right To Try law.
StemVacs is an immunotherapy platform that consists of 5 components. The overarching approach to the StemVacs Immunotherapy Platform is as follows:
1. Treat innate immune suppression: Administration of oral apigenin/NanoStilbene (Cancer DeTox Product) to decrease immune suppressive toxic molecules made by tumor and tumor microenvironment.
2. Treat adaptive immune suppression: Administration of MemoryMune to activate dormant memory cells recognizing the tumor. Administration of LymphoBoost to repair deficient IL-12 production.
3. Stimulation of immune response to cancer stem cells (StemVacs).
4. Consolidation and maintenance of immunity: Cycles of StemVacs, supported by innaMune and LymphoBoost